Rheb phosphorylation is involved in p38-regulated/activated protein kinase-mediated tumor suppression in liver cancer

Zheng,Min; Zang,Shengbing; Xie,Linna; Fang,Xueting; Zhang,Yu; Ma,Xiaojie; Liu,Jingfeng; Lin,Dexin; Huang,Aimin

doi:10.3892/ol.2015.3406

Rheb phosphorylation is involved in p38-regulated/activated protein kinase-mediated tumor suppression in liver cancer

Authors:
- Min Zheng
- Shengbing Zang
- Linna Xie
- Xueting Fang
- Yu Zhang
- Xiaojie Ma
- Jingfeng Liu
- Dexin Lin
- Aimin Huang
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China, Department of Pathology and Institute of Oncology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian 350004, P.R. China, Liver Center of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China
Published online on: June 22, 2015 https://doi.org/10.3892/ol.2015.3406
Pages: 1655-1661

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ras homolog enriched in brain (Rheb) is a key regulator of mammalian target of rapamycin complex 1 (mTORC1). The Rheb‑mTORC1 axis is a pivotal pathway that mediates cell growth. It was previously reported that upon energy‑stress stimulation, the phosphorylation of Rheb at serine 130 by p38‑regulated/activated protein kinase (PRAK) results in the impaired nucleotide binding ability of Rheb and inhibits Rheb‑mediated mTORC1 activation. However, the role of Rheb phosphorylation in cancer development remains to be elucidated. The aim of the present study was to determine the effect of Rheb phosphorylation on tumor growth in vitro and in vivo. In addition, tissue samples were obtained from 70 hepatocellular carcinoma (HCC) patients in order to determine any associations between Rheb phosphorylation and the clinicopathological characteristics of patients. In vitro and ex vivo kinase assays were performed to determine the phosphorylation of Rheb by PRAK. A xenograft assay was performed to assess tumorigenicity of MEF cell lines. In addition, western blot and immunohistochemical analyses were performed to detect Rheb protein expression and phosphorylation. The results of the present study revealed that Rheb phosphorylation may be induced through Ras overexpression. In addition, kinase‑dead PRAK and dominant‑negative PRAK mutation were demonstrated to abolish the Rheb phosphorylation induced by Ras overexpression. Xenograft assays in nude mice revealed that Rheb phosphorylation was involved in PRAK‑mediated tumor suppression. Of note, the clinicopathological analysis of 70 HCC samples determined that Rheb phosphorylation was associated with poor proliferation and the progression of HCC. In conclusion, the results of the present study suggested that Rheb phosphorylation may have an important role as an intracellular barrier to cancer development.

View Figures

View References

1	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
2	Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Shen Q, Ahn YM, Kwon SH, et al: DBC1 does not function as a negative regulator of SIRT1 in liver cancer. Oncol Lett. 4:873–877. 2012.PubMed/NCBI
3	Dimauro T and David G: Ras-induced senescence and its physiological relevance in cancer. Curr Cancer Drug Targets. 10:869–876. 2010. View Article : Google Scholar : PubMed/NCBI
4	Serrano M, Lin AW, McCurrach ME, Beach D and Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:593–602. 1997. View Article : Google Scholar : PubMed/NCBI
5	Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T and Schmitt CA: Oncogene-induced senescence as an initial barrier in lymphoma development. Nature. 436:660–665. 2005. View Article : Google Scholar : PubMed/NCBI
6	Ferbeyre G: Barriers to Ras transformation. Nat Cell Biol. 9:483–485. 2007. View Article : Google Scholar : PubMed/NCBI
7	New L, Jiang Y and Han J: Regulation of PRAK subcellular location by p38 MAP kinases. Mol Biol Cell. 14:2603–2616. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, et al: PRAK is essential for ras-induced senescence and tumor suppression. Cell. 128:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yamagata K, Sanders LK, Kaufmann WE, Yee W, Barnes CA, Nathans D and Worley PF: Rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J Biol Chem. 269:16333–16339. 1994.PubMed/NCBI
10	Inoki K, Li Y, Xu T and Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17:1829–1834. 2003. View Article : Google Scholar : PubMed/NCBI
11	Babcock JT and Quilliam LA: Rheb/mTOR activation and regulation in cancer: Novel treatment strategies beyond rapamycin. Curr Drug Targets. 12:1223–1231. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wazir U, Newbold RF, Jiang WG, Sharma AK and Mokbel K: Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer. Oncol Rep. 29:1969–1974. 2013.PubMed/NCBI
13	Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, et al: Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res. 70:3287–3298. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zheng H, Liu A, Liu B, Li M, Yu H and Luo X: Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. Cancer Lett. 297:117–125. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zheng M, Wang YH, Wu XN, Wu SQ, Lu BJ, Dong MQ, Zhang H, Sun P, Lin SC, Guan KL, et al: Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nat Cell Biol. 13:263–272. 2011. View Article : Google Scholar : PubMed/NCBI
16	Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J and Gores GJ: Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008. View Article : Google Scholar : PubMed/NCBI
17	Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
18	Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998. View Article : Google Scholar : PubMed/NCBI
19	Shengbing Z, Feng LJ, Bin W, Lingyun G and Aimin H: Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma. Anat Rec (Hoboken). 292:1128–1134. 2009. View Article : Google Scholar : PubMed/NCBI
20	Eom M, Han A, Lee MJ and Park KH: Expressional difference of RHEB, HDAC1, and WEE1 proteins in the stromal tumors of the breast and their significance in tumorigenesis. Korean J Pathol. 46:324–330. 2012. View Article : Google Scholar : PubMed/NCBI
21	Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O and Inoue T: Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation. Prostate. 70:866–874. 2010.PubMed/NCBI
22	Prieur A and Peeper DS: Cellular senescence in vivo: A barrier to tumorigenesis. Curr Opin Cell Biol. 20:150–155. 2008. View Article : Google Scholar : PubMed/NCBI
23	Menendez JA and Alarcón T: Metabostemness: a new cancer hallmark. Front Oncol. 4:2622014. View Article : Google Scholar : PubMed/NCBI
24	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
25	Aksamitiene E, Kiyatkin A and Kholodenko BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance. Biochem Soc Trans. 40:139–146. 2012. View Article : Google Scholar : PubMed/NCBI
26	Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C and Pandolfi PP: Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22:2172–2177. 2008. View Article : Google Scholar : PubMed/NCBI
27	Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J and Wendel HG: Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22:2178–2188. 2008. View Article : Google Scholar : PubMed/NCBI